Steglatro: Amida Care P&T Review
P&T Meetings
In March 2018, Amida Care invited me to present at their Pharmacy and Therapeutics Committee Meeting to add the SGLT2 inhibitor, Steglatro, to formulary. After discussion and comparing to other SGLT2 inhibitors, the formulary recommendation was accepted.
The presentation can be accessed using the link below.